Juarez M et al., 2018-02-01: Review by the Mexican group arguing that ivermectin's antitumour effects occur at clinically reachable concentrations, citing human PK studies; it also repeats the incorrect statement that ivermectin was FDA-approved for human use in 1987.
Importantly, the in vitro and in vivo antitumor activities of ivermectin are achieved at concentrations that can be clinically reachable based on the human pharmacokinetic studies done in healthy and parasited patients.
Juarez M et al., 2018-02-01: Review by the Mexican group arguing that ivermectin's antitumour effects occur at clinically reachable concentrations, citing human PK studies; it also repeats the incorrect statement that ivermectin was FDA-approved for human use in 1987. C6, and the source of the 'clinically achievable' framing. Study type: narrative review (no new data). Country: Mexico (Instituto Nacional de Cancerologia / UNAM). Funder/conflicts: the PubMed record gives 'Conflict of interest statement: None.' The review's assertion is about tissue concentrations inferred from PK studies and is contradicted in arithmetic by the label Cmax (IVA-23) and by Schmith et al. (IVA-25): 46.6 ng/mL is ~0.05 uM against the 5-10 uM used in the cell work. Also note the review says ivermectin is 'FDA-approved for human use in 1987' – the same error as the book; the US approval was 1996 (IVA-02) and 1987 was the year of the Mectizan donation/registration (IVA-03, IVA-04). Also filed as IVC-01, IVB-40 (claims C1, C6, C9). Study type: review.
